Machida, A.; Oishi, A.; Ikeda, J.; Kurihara, J.; Yoneda, A.; Tsuiki, E.; Hirata, Y.; Murakami, R.; Kitaoka, T.
Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life 2024, 14, 476.
https://doi.org/10.3390/life14040476
AMA Style
Machida A, Oishi A, Ikeda J, Kurihara J, Yoneda A, Tsuiki E, Hirata Y, Murakami R, Kitaoka T.
Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life. 2024; 14(4):476.
https://doi.org/10.3390/life14040476
Chicago/Turabian Style
Machida, Akira, Akio Oishi, Junichiro Ikeda, Junko Kurihara, Ai Yoneda, Eiko Tsuiki, Yuki Hirata, Ryuya Murakami, and Takashi Kitaoka.
2024. "Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept" Life 14, no. 4: 476.
https://doi.org/10.3390/life14040476
APA Style
Machida, A., Oishi, A., Ikeda, J., Kurihara, J., Yoneda, A., Tsuiki, E., Hirata, Y., Murakami, R., & Kitaoka, T.
(2024). Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept. Life, 14(4), 476.
https://doi.org/10.3390/life14040476